Modest weight loss improves leptin to adiponectin ratio and induces insulin and leptin resensitivization in individuals with obesity.

Victoria Therese Isaksen (dr.isaksen@gmail.com)
UiT The Arctic University of North Norway  https://orcid.org/0000-0003-2121-0755

Maria Arlen Larsen
UiT The Arctic University of Norway: UiT Norges arktiske universitet

Rasmus Goll
UiT The Arctic University of Norway: UiT Norges arktiske universitet

Eyvind J. Paulssen
UiT The Arctic University of Norway: UiT Norges arktiske universitet

Jon Ragnar Florholmen
UiT The Arctic University of Norway: UiT Norges arktiske universitet

Research

Keywords: Insulin resistance, Leptin resistance, Leptin to adiponectin ratio, Leptin, Adiponectin, Metabolic syndrome, Obesity, Postprandial triglycerides, Weight loss

Posted Date: October 1st, 2021

DOI: https://doi.org/10.21203/rs.3.rs-936579/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background Weight loss is important to reduce the risk of metabolic complications in obese individuals, in whom dysregulated adipokines play a central role. This study aims to investigate whether dysregulated adipokines and postprandial triglycerides (TG) improve with a modest weight loss. Methods Individuals with obesity were recruited among patients at the University Hospital of North Norway and the Stamina Health weight loss rehabilitation program. We measured resting energy expenditure (REE), and calculated the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), leptin to adiponectin (L:A) ratio, indirect leptin sensitivity (REE:leptin ratio), postprandial TG clearance at 6 h, and TG response before and after weight loss. The goal of the weight loss intervention was a loss of ≥5% of initial total body weight. Results Of the 28 participants who attended two scheduled assessments, 13 lost ≥5% body weight. HOMA-IR (-23.1%), REE:leptin ratio (+80.1%) and L:A ratio (-45.7%) significantly improved with weight loss, whereas there was no improvement of postprandial TG response or clearance. No significant changes were observed in the non-weight loss group. Conclusion Metabolic dysregulation, as insulin and leptin resistance, but not postprandial TG improve with a modest weight loss in individuals with obesity.

Background

Overweight and obesity are important risk factors for morbidity and mortality (1, 2), mainly because of their association with metabolic dysfunction and increased risk of cardiovascular disease (CVD), cancer, and type 2 diabetes mellitus (T2DM) (1, 3).

Dyslipidaemia is an essential part of the metabolic syndrome, in addition to abdominal obesity and insulin resistance (4). We have previously demonstrated that the postprandial triglyceride response (TGR) is altered in healthy individuals with obesity, with a delayed postprandial triglyceride (TG) clearance compared to healthy, normal weight individuals (5). Because humans spend most of their waking hours in the postprandial state, this increased period of triglyceride exposure in obese individuals contributes to an increased risk of both CVD and T2DM, by increasing atherosclerosis and induce insulin resistance (6, 7).

The adipokines leptin and adiponectin are, together with free fatty acids (FFA), critical mediators in adipocytes to maintain metabolic homeostasis (8-10). Moreover, adipokines play a central role in modulating inflammation (11, 12), another contributing mechanism to CVD. In individuals with overweight and obesity, alterations of adipokine levels and their function are essential factors of the pathophysiologic mechanisms causing the metabolic syndrome, CVD, T2DM and other complications to obesity (12, 13).

Obesity is related to leptin resistance, a well-known concept first described in 2000 (14). Leptin levels are correlated to fat mass and thus signals energy balance (16). Obese individuals are almost always hyperleptinaemic while having a normal resting energy expenditure (REE), whereas normal weight individuals maintain a normal REE on lower leptin levels (17). Reduced leptin levels signal energy
deficiency, which in turn induces counter-regulatory responses, of which reduced REE is one (16). Thus, the effect of leptin on REE seems to be feasible as an indirect marker of leptin sensitivity, by using the REE to leptin (REE:leptin) ratio (17).

Leptin and adiponectin changes are seen after a fatty meal in normal weight individuals, but not in obese individuals (18). Furthermore, the leptin to adiponectin (L:A) ratio has been proven to correlate well with other aspects of metabolic dysregulation and risk of chronic metabolic disease (19, 20). Individuals with obesity and elevated L:A ratio tend to have a delayed TG clearance, as well as both insulin and leptin resistance, making the L:A ratio a useful surrogate marker for the metabolic syndrome (18).

A modest weight loss of ≥5% improves metabolic disturbances and clinical features of the metabolic syndrome and complications of T2DM, with the improvement of insulin sensitivity being a crucial element (21, 22). Furthermore, because of compensatory metabolic mechanisms during weight loss, a modest weight loss might be easier to maintain in the long run than a >10% weight loss (23). Improvement of central leptin satiety signalling, as expressed in feeding behaviour, with weight loss and reduced leptin levels have previously been demonstrated (15). However, to our knowledge, documentation of leptin resensitization has only been described in experimental animal weight loss models, not in humans (15).

Thus, this study aimed to investigate if a modest weight loss of ≥5% is sufficient for significant improvement of the L:A ratio over the cut-off values previously identified (18), and if a corresponding improvement of other biomarkers of subclinical metabolic dysregulation occurs (18, 24).

**Materials And Methods**

We recruited participants from the Centre for Obesity, Department of Gastroenterology and Nutrition, from the obesity rehabilitation program at Stamina Health Tromsø and by posters placed at the Department of Clinical Nutrition and Department of Endocrinology at the University Hospital of North Norway (UNN). Eligible patients were provided with oral and written information and signed a written consent to participate.

Inclusion of participants is shown in Figure 1.

Inclusion criteria for the study population were a baseline body mass index (BMI) ≥30 kg/m² and age ≥18 years. Exclusion criteria were smoking, pregnancy, severe mental illness, previous heart disease, medically treated diabetes mellitus and kidney failure. We excluded patients who, for any reason, dropped out of the weight loss program. Height, body weight, blood pressure and pulse were measured. Total, abdominal and gynoid fat percentage, total fat mass (kg) and total muscle mass (kg) were obtained from body composition measured at baseline and follow-up after weight loss treatment, using Dual-Energy X-ray Absorptiometry (DEXA; Lunar Prodigy Advance, GE Health Care, USA).

*Normal weight control group*
For our control group we recruited 17 healthy, normal weight participants from the general population. Inclusion criteria were BMI in normal range, between 18 and 40 years of age, normotensive, normoglycaemic, normolipaemic and no history of diabetes. Exclusion criteria were otherwise the same as for our obese participants. The control participants underwent the same measurements and tests as our obese participants. Their results were used to create 95% confidence intervals (CI) for normal values in our metabolic parameters.

**Weight loss intervention**

The weight loss goal for the participants with obesity was a minimum of $\geq 5\%$ of the baseline body weight, as this amount of weight loss is accepted as clinically meaningful (24). The post-weight loss tests were performed within two years after the weight loss intervention. A shortened follow-up period was selected for participants who lost weight quickly, in order to avoid loss to follow-up due to weight regain.

Weight loss intervention was performed either individually or in treatment groups in the programs from where participants were recruited. The intervention was based on Norwegian national guidelines for diet and exercise (25, 26). Since the study aimed to investigate the effects of weight loss *per se*, the instructions for weight loss methods were kept liberal and not formally recorded. Participants were free to adjust their diet and exercise according to their own preferences, within national guidelines.

All 50 participants who underwent baseline tests were offered to undergo the second round of tests regardless of the amount of weight loss during follow-up. 22 out of 37 participants in the non-weight loss group declined the offer and was hence lost to follow-up, while 15 accepted. All 13 participants in the weight loss group accepted the offer.

**Insulin sensitivity**

We performed a 2 h Oral Glucose Tolerance Test (OGTT) (18). Participants had their regular diet and abstained from vigorous exercise three days before the test and showed up at 08:00 am after 12 h of overnight fasting. The test was conducted by oral intake of 75 g glucose dissolved in water (27). We collected blood samples in both the fasting state and 30, 60, 90 and 120 minutes after glucose intake, in which serum (s-) glucose and s-insulin were measured using ELISA kits (DRG Insulin Elisa kit, DRG Instruments GmbH, Germany) (5). We determined insulin sensitivity by calculation of the HOMA-IR (28), as it has previously proven to correspond well to the whole body insulin sensitivity index (WBISI) (27, 29).

**S-leptin and adiponectin measurements**

Both leptin and free adiponectin were analysed from frozen serum drawn at all sample times, both during OFTT and OGTT, using ELISA kits (DRG Diagnostics, Marburg, Germany) for leptin (sandwich ref. EIA-2395) and adiponectin (human, ref. EIA-4574), respectively. From these measurements, the L:A ratio was calculated as follows:
As the intra individual variation was minimal between OFTT and OGTT measurements, OFTT values were selected for the statistical analyses.

**Leptin sensitivity**

Leptin sensitivity was calculated as the ratio of Resting Energy Expenditure (REE) to fasting s-leptin (17, 30). We performed REE measurements by a canopy test with an indirect calorimetry device from Medical Graphics CPX metabolic cart (St Paul, MN, USA). The test protocol is previously described (18). After the completion of REE measurement, the OGTT was performed (17).

**Postprandial triglyceride clearance**

To measure postprandial TGR and TG clearance, we performed an Oral Fat Tolerance Test (OFTT) on a separate day from the OGTT (31, 32). Preparations for the OFTT were the same as for the OGTT. Fasting blood samples were drawn, and a meal of sour cream porridge was served, containing 1 g of fat per kg of body weight (32). The participants ingested the meal within 30 minutes, and blood samples were drawn from the antecubital vein in a seated position at baseline and 2, 4, 6 and 8 h postprandially.

The Department for Clinical Biochemistry at UNN analyzed fasting serum samples for TG, total cholesterol, low density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol. All samples were analysed using the same methods, equipment and reference values as the study by Larsen *et al.* (5).

The TGR was defined as the average of the two highest postprandial TG concentrations, minus the baseline concentration (5, 32).

The formula for calculating TG clearances (32) at time X was as follows:

\[
\text{Clearance } Xh = 100 \times \left( 1 - \frac{TG_X - TG_{0h}}{TG_{\text{max}} - TG_{0h}} \right)
\]

**Cut-off values for metabolic parameters**

Normalization of metabolic parameters were defined as reaching the 95% CI of our healthy, normal weight control group. The cut-off values were as follows: TG clearance at 6 h ≥88%, TGR ≤ .67, HOMA-IR ≤1.83, WBISI ≥131.4, L:A ratio ≤1.19 and REE:leptin ratio ≥114.5 (18).

**Statistics**
For statistical calculations, we used IBM SPSS Statistics 25 for Windows (SPSS Inc., Chicago, IL, USA). For calculating TG clearance and postprandial TGR, we used Microsoft Excel (Microsoft corp., Redmond, WA, USA). Plots were generated in GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA).

We used parametric tests on raw or transformed variables that resembled a normal distribution visually or by skewness/kurtosis. Otherwise, non-parametric tests were performed.

**Results**

**Baseline characteristics**

We included 28 Caucasian participants in this study with a weight loss of 0-30%. Seven participants (25%) were male and 21 (75%) were female. Among these, 15 participants (54%) lost < 5% body weight whereas 13 participants (46%) lost ≥ 5% body weight, including 5 participants (18%) who lost ≥10%. Median weight loss in the weight loss group was 10.0 kg.

Clinical, anthropometric, and metabolic characteristics are shown in Table 1. There were no significant differences in baseline characteristics between the weight loss and non-weight loss group, with the exception of REE (p= 0.006), TG (p=0.011) and HDL-cholesterol (p= 0.004) levels. For leptin and adiponectin measurements, only data from OFTT samples are shown.

Four participants (three in the weight loss group, one in the non-weight loss group) used antihypertensive medication at baseline, two used thyroid replacement drugs (one in each group) and three used lipid lowering drugs (three in the weight loss and one in the non-weight loss group). Two participants in the weight loss group had hypertension at baseline. All female participants except one had LDL-cholesterol levels <4.3 mmol/L, the upper limit of normal for females <50 years. All male participants except one had LDL-cholesterol levels <4.7 mmol/L, the upper limit of normal for males <50 years.

Our normal weight controls had a median fasting s-leptin of 8.5 ng/mL and fasting s-adiponectin of 11.8 μg/mL.

**L:A ratio**

There were significant improvements between pre- and post-intervention visits for fasting s-leptin and L:A ratio for the weight loss group, but not for the non-weight loss group (Table 2). Participants with weight loss had a 45.7% (p = 0.002) improvement in L:A ratio (Table 2).

Figure 2 shows the case-by-case change in central variables before and after weight loss intervention. Most notably is the significant improvement in L:A ratio in participants in the weight loss group. The improvement was even greater in the subgroup of ≥10 % weight loss, but not reaching the level of normality (cut-off value ≥1.88, p = 0.030, figure 2). In the non-weight loss group no significant changes were observed (p= 0.020).
**Leptin sensitivity**

The REE:leptin ratio improved with 80.1% (p = 0.005) in the weight loss group (table 2) but not in the non-weight loss group. Furthermore, there was a tendency of greater improvements in leptin sensitivity in the subgroup of ≥10% weight loss, compared to 5-10% weight loss. Four of the 13 (31%) participants in the subgroup achieved normalized leptin sensitivity after weight loss (REE:leptin ratio ≥114.5, figure 2). No significant changes were observed in the non-weight loss group (p= 0.013).

**Insulin sensitivity**

Insulin sensitivity measured by HOMA-IR improved with 23.1% (p = 0.011) in the weight loss group, where nine out of the 13 (69%) participants had normal HOMA-IR values after weight loss (HOMA-IR ≤ 1.83). Of these, five participants improved from insulin resistance at baseline.

There also was a significant improvement of 49.9% in WBISI in the weight loss group (p= 0.008). Two participants in this group normalized their WBISI, while one participant maintained a normal baseline WBISI. There also was a significant difference in WBISI delta values between weight loss and non-weight loss group (p=0.013, Mann-Whitney U test).

No significant changes were observed in the non-weight loss group for neither HOMA-IR nor WBISI (Table 2, figure 2).

**Improvement of postprandial triglycerides**

No significant differences in postprandial TG clearance at 6 h were seen in any of the groups (6.6%, p = 0.807). (Table 2, figure 2).

**Discussion**

In this study we have examined the L:A ratio, indirect leptin sensitivity, insulin sensitivity, and postprandial TG metabolism in obese participants before and after a modest weight loss of ≥5%. We found significant improvements in L:A ratio (-45.7%), leptin sensitivity (-80.1%) and insulin sensitivity (-23.1%) in participants who achieved weight loss, compared to participants with no weight loss. Furthermore, our study shows that as little as ≥5% weight loss improve adipokines, but not TG metabolism.

We have previously reported that the L:A ratio is a feasible surrogate biomarker for early detection of metabolic disturbances in obesity (19). Moreover, we have previously reported a potential postprandial regulatory role of adiponectin and leptin which is impaired in obesity (18). The L:A ratio has been demonstrated to improve after a weight loss of 5-10% by Ferreira et al. and Talaei et al, among others. (33, 34).

Our present findings demonstrate an improvement in L:A ratio of -45.7% in a small group of 13 participants with weight loss. Such a large improvement in this small dataset has major clinical implications.
significance, and supports a realistic weight loss goal that is potentially easier to maintain long term (23). The improvement of the L:A ratio is important as it is known to correlate to low-grade inflammation and thus risk of CVD (36, 37).

Frühbeck et al. proposed adiponectin:leptin ratio cardiovascular risk category limits as follows: normal risk $\geq 1$, moderate risk 0.5-1 and high risk <0.5 (37). Inversely, this translates to our L:A ratio category limits of $\leq 1$, 1-2 and >2, respectively. According to these limits of risk, three participants with weight loss crossed from high to moderate cardiovascular risk after weight loss while one participant crossed from moderate to low risk and one from high to low risk. In total 38% of the participants reduced their risk category.

A study by Bi et al. suggests that leptin contributes significantly more to the variance in REE than what is explained by fat mass (30). Furthermore, Rosenbaum et al. demonstrated that leptin administration reversed the decrease in energy expenditure after weight loss (38). We found that REE:leptin ratio improved with a median of 80.1%. In addition, approximately one third (31%) of the participants in the weight loss group had their REE:leptin ratio normalized after weight loss (18). Although resensitivization of leptin on satiety signalling is not possible to measure clinically in humans, one can speculate whether this demonstration of indirect resensitivization of leptin suggest a normalization of central leptin sensitivity as well.

Insulin sensitivity, as measured by the HOMA-IR or WBISI, improved by 23.1 % and 49.9%, respectively, after weight loss. Moreover, five out of the 13 (39%) participants obtained normalized insulin sensitivity as defined by HOMA-IR, while two out of 13 (13%) normalized it as defined by WBISI (18, 30). This is in agreement with most other reports (22). The improved insulin sensitivity observed together with an improved L:A ratio is also in agreement with previous reports, describing a correlation between the two variables (42). Our findings of a substantial percentage of normalized insulin sensitivity further support the conclusion that a 5% weight loss is clinically meaningful for reducing obesity complications.

There were no significant improvement of postprandial TG clearance after $\geq 5\%$ weight loss. This could be explained by the small number of participants that lost $\geq 10\%$ body weight. Magkos et al. reported that improvements of TG and FFA were observed first after 11% and 16% weight loss, respectively (21). Therefore, normalization of postprandial TG clearance will most likely be observed only after a substantial weight loss in obese individuals.

The strengths of the present study are the use of various methods, particularly adipokine levels, reflecting the patophysiological mechanisms behind metabolic disorders in obesity to make comprehensive explanations of the results obtained by a modest weight loss. In addition to this, the generalizability of the weight loss method used in the study is high, as we did not assign one specific diet or exercise plan to our participants. We also included participants from different sources with broad inclusion criteria. The study was performed in a clinical setting, which also makes the generalizability high.
The main weakness of our study design is the dropout rate and small sample size that renders us unable to perform parametric tests and to perform more complex analyses (ANOVA, etc.). Due to the sample size we mainly used repeated measures analyses, thus reducing the variability in our samples, making our results more reliable under the given circumstances.

There is also a significant imbalance between men and women included in our study. This could affect our results, as body composition and hence leptin concentrations differ between the sexes (43). However, the gender differences in our study is in accordance with other studies of obesity, and also with literature on such differences in the population of patients seeking help for health problems in general (44).

In conclusion, a modest weight loss of $\geq 5\%$ improves sensitive metabolic surrogate markers like L:A ratio, leptin sensitivity (REE:leptin ratio) and insulin sensitivity. However, markers of postprandial TG clearance did not improve at the present level of weight loss. Our results support that a realistic and achievable weight loss goal of $\geq 5\%$ for obese individuals does reduce the risk of metabolic complications.

**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>Apo</td>
<td>Apolipoprotein (A1, B and E)</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CVD</td>
<td>Cardiovascular disease</td>
</tr>
<tr>
<td>DEXA</td>
<td>Dual-energy X-ray absorptiometry</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>FFA</td>
<td>Free fatty acids</td>
</tr>
<tr>
<td>$\gamma$-GT</td>
<td>Gamma glutamyl transferase</td>
</tr>
<tr>
<td>h</td>
<td>Hours</td>
</tr>
<tr>
<td>HDL</td>
<td>High-density lipoprotein</td>
</tr>
</tbody>
</table>
HOMA-IR  Homeostasis model assessment of insulin resistance
L:A  Leptin to adiponectin (ratio)
LDL  Low-density lipoprotein
OGTT  Oral glucose tolerance test
OFTT  Oral fat tolerance test
REE  Resting energy expenditure
REK  Regional Etisk Komité (Regional Ethics Committee)
TG  Triglyceride
TGR  Triglyceride response
UiT  University of Tromsø
UNN  University hospital of North Norway
WBISI  Whole body insulin sensitivity index

Declarations

Availability of data and materials: The dataset supporting the conclusions of this article is available in the UiT Open Research Data repository at https://doi.org/10.18710/KRYLXN

Competing interests: The authors have nothing to disclose.

Funding: This study was funded by the Medical Students Research Programme at the Faculty of Health Sciences, UiT The Arctic University of Norway. The publication charges for this article have been funded by a grant from the publication fund of UiT The Arctic University of Norway

Ethics: All participants signed a written consent form. The Regional Ethics Committee of North Norway (2011/1677/REK Nord) approved the study. Consent for publication of results was not applicable, as no individual participant is identifiable in this paper.

Author’s contributions: Authors VTI and MAL conducted participant inclusion and data collection. MAL performed weight loss follow-up for some of the participants. VTI and RG performed statistical analyses. JF was the principal investigator.

All authors participated in the planning of the study, the interpretation of results and the process of writing and editing the manuscript.
Acknowledgements: The authors are sincerely grateful for the contributions to this study done by the staff at the Gastroenterological Laboratory, UNN. Clinical research nurse Odd Sverre Moen contributed significantly to participant examinations. Bioengineers Marian Remijn and Line Wilsgaard analysed adipokine samples and performed DEXA and REE tests. Centre for Obesity nurse Torunn Dreyer recruited study participants and carried out participant follow-up, including weight loss treatment. Clinical nutritionist Hugo Nilssen and the staff at Stamina Health, Tromsø also contributed significantly to weight loss follow-up.

References


40. . !!! INVALID CITATION !!! (18).


**Tables**

**Table 1:** Baseline characteristics of the 28 overweight participants and 17 normal weight controls
<table>
<thead>
<tr>
<th></th>
<th>Normal weight controls</th>
<th>Weight loss ≥ 5 %</th>
<th>Weight loss &lt; 5 %</th>
<th>Sig. (p)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>2/15</td>
<td>2/11</td>
<td>5/10</td>
<td>0.282</td>
</tr>
<tr>
<td>Age</td>
<td>31.0 (13)</td>
<td>39.8 (13)</td>
<td>36.0 (19)</td>
<td>0.254\textsuperscript{M}</td>
</tr>
<tr>
<td>BMI (kg/m\textsuperscript{2})</td>
<td>21.3 (2.2)</td>
<td>33.6 (11.5)</td>
<td>39.8 (7.5)</td>
<td>0.217\textsuperscript{M}</td>
</tr>
<tr>
<td>Total body fat (%)</td>
<td>26.6 (5.9)</td>
<td>50.5 (9.5)</td>
<td>49.1 (9.1)</td>
<td>0.142\textsuperscript{M}</td>
</tr>
<tr>
<td>Abdominal fat (%)</td>
<td>27.5 (6.4)</td>
<td>58.2 (7.9)</td>
<td>56.7 (3.9)</td>
<td>0.895\textsuperscript{G}</td>
</tr>
<tr>
<td>Gynoid fat (%)</td>
<td>36.3 (5.8)</td>
<td>54.5 (9.1)</td>
<td>53.6 (9.8)</td>
<td>0.118\textsuperscript{M}</td>
</tr>
<tr>
<td>REE (kcal/day)</td>
<td>1356 (185)</td>
<td>1604 (441)</td>
<td>1989 (465)</td>
<td>0.006\textsuperscript{M}</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>105 (15)</td>
<td>124 (22)</td>
<td>128 (15)</td>
<td>0.525\textsuperscript{M}</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>65 (10)</td>
<td>80 (17)</td>
<td>75 (9)</td>
<td>0.208\textsuperscript{G}</td>
</tr>
<tr>
<td>Fasting Glucose (mmol/L)</td>
<td>4.4 (0.7)</td>
<td>5.4 (1.3)</td>
<td>5.1 (1.0)</td>
<td>0.892\textsuperscript{M}</td>
</tr>
<tr>
<td>Fasting Insulin ((\mu\text{mol/L}))</td>
<td>5.5 (2.9)</td>
<td>10.8 (6.2)</td>
<td>13.2 (6.1)</td>
<td>0.142\textsuperscript{M}</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.1 (0.7)</td>
<td>2.7 (1.8)</td>
<td>3.1 (1.9)</td>
<td>0.170\textsuperscript{M}</td>
</tr>
<tr>
<td>WBISI</td>
<td>147.8 (101.5)</td>
<td>55.1 (45.6)</td>
<td>55.2 (31.2)</td>
<td>0.467\textsuperscript{M}</td>
</tr>
<tr>
<td>Fasting TG (mmol/L)</td>
<td>1.0 (0.4)</td>
<td>1.2 (0.7)</td>
<td>1.5 (0.6)</td>
<td>0.011</td>
</tr>
<tr>
<td>TGR (mmol/L)</td>
<td>0.3 (0.3)</td>
<td>0.6 (0.4)</td>
<td>1.0 (0.9)</td>
<td>0.586\textsuperscript{M}</td>
</tr>
<tr>
<td>TG clearance 6 hrs (%)</td>
<td>115.4 (62.3)</td>
<td>65.0 (96)</td>
<td>61.1 (46)</td>
<td>0.413\textsuperscript{M}</td>
</tr>
<tr>
<td>Leptin (ng/mL)</td>
<td>8.5 (7.4)</td>
<td>32.5 (37.0)</td>
<td>41.7 (21.8)</td>
<td>0.928\textsuperscript{M}</td>
</tr>
<tr>
<td>Adiponectin ((\mu\text{g/mL}))</td>
<td>11.8 (7.1)</td>
<td>9.0 (3.7)</td>
<td>6.8 (3.7)</td>
<td>0.525\textsuperscript{M}</td>
</tr>
<tr>
<td>L:A ratio</td>
<td>0.6 (0.9)</td>
<td>3.8 (2.5)</td>
<td>6.1 (35.2)</td>
<td>0.683\textsuperscript{M}</td>
</tr>
<tr>
<td>REE:Leptin ratio</td>
<td>142.5 (134.0)</td>
<td>54.1 (51.6)</td>
<td>47.8 (51.6)</td>
<td>0.683\textsuperscript{M}</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.2 (0.9)</td>
<td>4.3 (1.2)</td>
<td>4.7 (1.1)</td>
<td>0.153\textsuperscript{G}</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>2.6 (1.3)</td>
<td>2.7 (1.4)</td>
<td>2.9 (0.9)</td>
<td>0.107</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.6 (0.5)</td>
<td>1.3 (0.2)</td>
<td>1.1 (0.2)</td>
<td>0.004</td>
</tr>
<tr>
<td>HDL:LDL ratio</td>
<td>0.57 (0.49)</td>
<td>0.52 (0.47)</td>
<td>0.35 (0.17)</td>
<td>0.009\textsuperscript{M}</td>
</tr>
</tbody>
</table>
Baseline anthropometric and metabolic characteristics for all participants. Significance tested between weight loss groups by t-test or Mann-Whitney non-parametric test (M). Parameters without normal variation distribution were transformed to geometric mean (\(G\)) if possible before the t-test was performed. Values shown as median (interquartile range). Abbreviations: BMI Body Mass Index. HDL High Density Lipoprotein. HOMA-IR Homeostasis Model Assessment of Insulin Resistance. L:A ratio Leptin:Adiponectin ratio. LDL Low Density Lipoprotein. REE Resting Energy Expenditure. TG Triglyceride. TGR Triglyceride Response. WBISI Whole Body Insulin Sensitivity Index

**Table 2:** *Post-intervention characteristics for the 28 participants*
<table>
<thead>
<tr>
<th></th>
<th>Weight loss ≥ 5 %</th>
<th></th>
<th>Weight loss &lt; 5 %</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Value</td>
<td>Per cent change</td>
<td>Sig. (p)^w</td>
<td>Value</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>81.1 (24.1)</td>
<td>-10.0 (7.1)</td>
<td>0.001</td>
<td>119.9 (18.8)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30.9 (8.9)</td>
<td>-8.2 (6.2)</td>
<td>0.001</td>
<td>39.5 (7.1)</td>
</tr>
<tr>
<td>Abdominal fat (%)</td>
<td>51.1 (7.6)</td>
<td>-7.4 (7.6)</td>
<td>0.001</td>
<td>55.6 (6.5)</td>
</tr>
<tr>
<td>Gynoid fat (%)</td>
<td>52.0 (11.3)</td>
<td>-5.4 (8.4)</td>
<td>0.002</td>
<td>51.2 (13.5)</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.4 (1.8)</td>
<td>-23.1 (51.6)</td>
<td>0.011</td>
<td>2.6 (1.3)</td>
</tr>
<tr>
<td>WBISI</td>
<td>92.1 (163.2)</td>
<td>49.9 (133.8)</td>
<td>0.008</td>
<td>67.2 (30.0)</td>
</tr>
<tr>
<td>L:A ratio</td>
<td>2.7 (2.2)</td>
<td>-45.7 (29.9)</td>
<td>0.002</td>
<td>5.0 (4.7)</td>
</tr>
<tr>
<td>REE:Leptin ratio</td>
<td>78.5 (72.9)</td>
<td>80.1 (92.6)</td>
<td>0.005</td>
<td>71.3 (68.0)</td>
</tr>
<tr>
<td>REE (kcal/day)</td>
<td>1459 (427)</td>
<td>-8.6 (15.6)</td>
<td>0.196</td>
<td>2095 (360)</td>
</tr>
<tr>
<td>Fasting TG (mmol/L)</td>
<td>1.1 (0.6)</td>
<td>-9.2 (66.0)</td>
<td>0.649</td>
<td>1.3 (1.2)</td>
</tr>
<tr>
<td>TGR (mmol/L)</td>
<td>.51 (0.59)</td>
<td>-33.6 (29.6)</td>
<td>0.327</td>
<td>.67 (1.03)</td>
</tr>
<tr>
<td>TG clearance 6 hrs (%)</td>
<td>75 (62.1)</td>
<td>6.6 (116.6)</td>
<td>0.807</td>
<td>66.0 (42.1)</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>121 (18)</td>
<td>0.0 (8.4)</td>
<td>0.074</td>
<td>120 (15)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>76 (20)</td>
<td>.6 (12.9)</td>
<td>0.248</td>
<td>69 (16)</td>
</tr>
<tr>
<td>Fasting Leptin (ng/mL)</td>
<td>20.5 (14.3)</td>
<td>-50.0 (36.3)</td>
<td>0.004</td>
<td>29.8 (27.8)</td>
</tr>
<tr>
<td>Fasting Adiponectin (µg/mL)</td>
<td>8.2 (4.6)</td>
<td>-4.1 (42.5)</td>
<td>0.576</td>
<td>7.1 (2.4)</td>
</tr>
<tr>
<td>Fasting Glucose (mmol/L)</td>
<td>5.0 (1.1)</td>
<td>-5.3 (11.8)</td>
<td>0.090</td>
<td>5.1 (1.6)</td>
</tr>
<tr>
<td>Fasting Insulin (µmol/L)</td>
<td>6.3 (6.6)</td>
<td>-16.6 (45.2)</td>
<td>0.006</td>
<td>8.3 (8.4)</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>2.8 (1.0)</td>
<td>-11.1 (34.9)</td>
<td>0.438</td>
<td>4.8 (1.0)</td>
</tr>
</tbody>
</table>
HDL cholesterol (mmol/L) 1.4 (0.3) -2 (19.3) 0.872 3.0 (8) 10.0 (21.2) 0.715

Post-intervention characteristics and per cent change from baseline characteristics for weight loss (≥5%) and non-weight loss (<5%) groups, respectively. Significance tested between baseline and post-treatment values by Related Samples Wilcoxon Rank Test (W). Values shown as median (interquartile range).


**Figures**

**Figure 1**

Flowchart of included participants from posters at UNN, obesity out-patient clinic at UNN and Stamina obesity rehabilitation program, respectively.
**Figure 2**

Difference between baseline and post intervention values of A) L:A ratio, B) Indirect leptin sensitivity (REE:Leptin ratio) C) HOMA-IR, D) TG clearance at 6 h and E) TGR before and after <5% and ≥5% weight loss in individual participants. Horizontal lines represent the upper or lower limit of 95% CI in healthy, normal weight controls.